Adverse events with isoniazid preventive therapy: Experience from a large trial

AIDS

Volumn 24, Issue SUPPL. 5, 2010, Pages

  Grant, Alison D ^a   Mngadi, Kathryn T ^b   Van Halsema, Clare L ^a   Luttig, Mariëtha M ^b   Fielding, Katherine L ^a   Churchyard, Gavin J ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b AURUM INSTITUTE   (South Africa)

Author keywords

adverse effects; HIV; isoniazid preventive therapy; tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; PYRIDOXINE;

ADULT; ALCOHOL CONSUMPTION; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DECREASED APPETITE; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENERGY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCREASED APPETITE; LIBIDO; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SOUTH AFRICA; STOMACH PAIN; THORAX RADIOGRAPHY; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; MINING; PREVALENCE; RADIOGRAPHY, THORACIC; SOUTH AFRICA; TUBERCULOSIS;

EID: 78649282690     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000391019.10661.66     Document Type: Article

References (21)

1. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010:CD000171.
2. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. World Health Organization. http://www.who.int/tb/publications/glo bal-report/2009/pdf/full-report.pdf [Accessed 29 August 2010].
3. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
4. Corbett EL, Churchyard GJ, Charalambous S, Samb B, Moloi V, Clayton TC, et al. Morbidity and mortality in South African gold miners: the impact of untreated HIV disease. Clin Infect Dis 2002; 34:1251-1258.
5. DAIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. http://rsc.tech-res.com/Docu ment/ safetyandpharmacovigilance/Table-for-Grading-Severity- of-Adult-Pediatric- Adverse-Events.pdf [Accessed 29 August 2010].
6. Lewis JJ, Charalambous S, Day JH, Fielding KL, Grant AD, Hayes RJ, et al. HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med 2009; 180:1271-1278.
7. Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew TB, Tedla Z, et al. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana experience, 2004-2006. J Acquir Immune Defic Syndr 2010; 54:71-77.
8. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12:2447-2457.
9. Hiransuthikul N, Nelson KE, Hiransuthikul P, Vorayingyong A, Paewplot R. INH preventive therapy among adult HIV-infected patients in Thailand. Int J Tuberc Lung Dis 2005; 9:270-275.
10. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137:640-647.
11. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117:991-1001.
12. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60:555-564.
13. Munseri PJ, Talbot EA, Mtei L, Fordham von Reyn C. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis 2008; 12:1037-1041.
14. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281:1014-1018.
15. Alperstein G, Morgan KR, Mills K, Daniels L. Compliance with antituberculosis preventive therapy among 6-year-old children. Aust N Z J Public Health 1998; 22:210-213.
16. Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005; 293:2719-2725.
17. Souza CT, Hokerberg YH, Pacheco SJ, Rolla VC, Passos SR. Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro. Mem Inst Oswaldo Cruz 2009; 104:462-467.
18. Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997; 337:315-320.
19. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337:801-808.
20. Mohammed A, Myer L, Ehrlich R, Wood R, Cilliers F, Maartens G. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Int J Tuberc Lung Dis 2007; 11:1114-1120.
21. Hawken MP, Meme HK, Elliott LC, Chakaya JM, Morris JS, Githui WA, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11:875-882.